Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered...

Descripción completa

Detalles Bibliográficos
Autores principales: Megaro, Giacomina, Rossi, Luigi, Ceddia, Serena, Sinjari, Marsela, Mannino, Adele, Gozzi, Elisa, Cosimati, Antonella, Brandi, Martina, Bitca, Victoria, Toscani, Ilaria, Cimino, Giuseppe, Tomao, Silverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275194/
https://www.ncbi.nlm.nih.gov/pubmed/32547382
http://dx.doi.org/10.1159/000507433
Descripción
Sumario:In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.

Ejemplares similares